Jazz Pharmaceuticals Plc Stock Revenue
| JAZZ Stock | USD 123.04 0.56 0.45% |
Jazz Pharmaceuticals PLC fundamentals help investors to digest information that contributes to Jazz Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Jazz Stock. The fundamental analysis module provides a way to measure Jazz Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Jazz Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 3.8 B | 4 B |
Jazz | Revenue |
Jazz Pharmaceuticals PLC Company Revenue Analysis
Jazz Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Jazz Pharmaceuticals Revenue | 3.83 B |
Most of Jazz Pharmaceuticals' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Jazz Pharmaceuticals PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Jazz
Projected quarterly revenue analysis of Jazz Pharmaceuticals PLC provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Jazz Pharmaceuticals match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Jazz Pharmaceuticals' stock price.
Jazz Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Jazz Pharmaceuticals is extremely important. It helps to project a fair market value of Jazz Stock properly, considering its historical fundamentals such as Revenue. Since Jazz Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Jazz Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Jazz Pharmaceuticals' interrelated accounts and indicators.
| 0.65 | 0.57 | -0.42 | 0.62 | 0.06 | ||
| 0.65 | 0.93 | -0.06 | 1.0 | 0.32 | ||
| 0.57 | 0.93 | -0.13 | 0.91 | 0.2 | ||
| -0.42 | -0.06 | -0.13 | -0.04 | 0.01 | ||
| 0.62 | 1.0 | 0.91 | -0.04 | 0.32 | ||
| 0.06 | 0.32 | 0.2 | 0.01 | 0.32 |
Click cells to compare fundamentals
Jazz Revenue Historical Pattern
Today, most investors in Jazz Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Jazz Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Jazz Pharmaceuticals revenue as a starting point in their analysis.
Jazz Pharmaceuticals Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Jazz Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Jazz Pharmaceuticals PLC reported 3.83 B of revenue. This is 49.73% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The revenue for all United States stocks is 59.36% higher than that of the company.
Jazz Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Jazz Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Jazz Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Jazz Pharmaceuticals by comparing valuation metrics of similar companies.Jazz Pharmaceuticals is currently under evaluation in revenue category among its peers.
Jazz Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Jazz Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Jazz Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Jazz Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Jazz Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Jazz Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Jazz Pharmaceuticals' value.| Shares | Camber Capital Management Llc | 2024-09-30 | 1.1 M | Franklin Resources Inc | 2024-09-30 | 1.1 M | Geode Capital Management, Llc | 2024-09-30 | 1.1 M | Citadel Advisors Llc | 2024-09-30 | 1.1 M | Renaissance Technologies Corp | 2024-09-30 | 1 M | Swedbank Ab | 2024-09-30 | 1 M | Vestal Point Capital Lp | 2024-09-30 | 900 K | Fmr Inc | 2024-09-30 | 835.9 K | Thompson, Siegel & Walmsley Llc | 2024-09-30 | 781.2 K | Blackrock Inc | 2024-06-30 | 6.1 M | Vanguard Group Inc | 2024-09-30 | 6.1 M |
Jazz Fundamentals
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0462 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | 10.88 B | ||||
| Shares Outstanding | 60.45 M | ||||
| Shares Owned By Insiders | 2.93 % | ||||
| Shares Owned By Institutions | 98.74 % | ||||
| Number Of Shares Shorted | 4.25 M | ||||
| Price To Earning | 35.18 X | ||||
| Price To Book | 1.79 X | ||||
| Price To Sales | 1.86 X | ||||
| Revenue | 3.83 B | ||||
| Gross Profit | 3.39 B | ||||
| EBITDA | 1.29 B | ||||
| Net Income | 414.83 M | ||||
| Cash And Equivalents | 899.36 M | ||||
| Cash Per Share | 14.28 X | ||||
| Total Debt | 5.79 B | ||||
| Debt To Equity | 2.12 % | ||||
| Current Ratio | 3.16 X | ||||
| Book Value Per Share | 69.01 X | ||||
| Cash Flow From Operations | 1.09 B | ||||
| Short Ratio | 6.16 X | ||||
| Earnings Per Share | 7.06 X | ||||
| Price To Earnings To Growth | 0.85 X | ||||
| Target Price | 180.0 | ||||
| Number Of Employees | 2.8 K | ||||
| Beta | 0.57 | ||||
| Market Capitalization | 7.44 B | ||||
| Total Asset | 11.39 B | ||||
| Retained Earnings | 878.66 M | ||||
| Working Capital | 1.9 B | ||||
| Current Asset | 1.26 B | ||||
| Current Liabilities | 226.64 M | ||||
| Net Asset | 11.39 B |
About Jazz Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Jazz Pharmaceuticals PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jazz Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jazz Pharmaceuticals PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Jazz Stock Analysis
When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.